0.140 s

+0.005 (+3.70%)
Range 0.130 - 0.140   (7.69%)
Open 0.139
Previous Close 0.135
Buy Price -
Buy Volume 11
Sell Price -
Sell Volume 10
Volume 14,736
Value -
Remark s
Measurement Type Value
EPS (USD) -0.378
Trailing EPS (USD) -0.299
NAV (USD) 0.569
Cash In Hand (USD) 0.268
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 0.615
Price / Cash In Hand 1.306
Issued & Paid-up Shares 33,638,000
Treasury Shares -
Market Cap (M) 11.773
Par Value (USD) n.a.
Beta - 75 Days -0.036
R-Squared - 75 Days(%) 0.01
Beta - 500 Days 0.13
R-Squared - 500 Days(%) 0.01
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 28 May 2022 03:39.
Data powered by
View All Events

About CYTRX CORP

CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.